Following on from information provided to NICE by the company in June 2009, the appraisal of Pancreatic cancer - capectitabine [ID389] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 389 |
| Referral date | 01 December 2007 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
| 2nd appraisal committee meeting | TBC |
Project Team
| Assessment Group / Evidence Review Group: | TBC |
| Communications manager: | Alice Law |
| Executive Lead: | Andrew Dillon |
| Project manager: | TBC |
| Technical Lead: | Andres Roman |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 November 2022 | Discontinued. Following on from information provided to NICE by the company in June 2009, the appraisal of Pancreatic cancer - capectitabine [ID389] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 26 June 2009 |
The manufacturer of capecitabine has advised us that they have not applied for regulatory approval in relation to this product at this time. The Institute has therefore decided to remove this appraisal from its current work programme. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. |
For further information on our processes and methods, please see our CHTE processes and methods manual